NCT02684461View on ClinicalTrials.gov

Phase II Trial of Sequential Consolidation With Pembrolizumab Followed by Nab-paclitaxel

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

September 13, 2016

Primary Completion Date

November 19, 2021

Study Completion Date

November 19, 2021

Conditions
Non Small Cell Lung Cancer
Interventions
DRUG

Pembrolizumab

"Receive Pembrolizumab 200 mg on day 1 every 21 days for four cycles.~Receive nab-paclitaxel 100 mg/m2 on day 1 and day 8 every 21 days for four cycles."

Trial Locations (5)

22031

Inova Schar Cancer Institute, Fairfax

27599

UNC Lineberger Comprehsive Cancer Center, Chapel Hill

27607

Rex Cancer Center, Raleigh

27614

Rex Cancer Center of Wakefield, Raleigh

75390

UT Southwestern Medical Center, Dallas

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

UNC Lineberger Comprehensive Cancer Center

OTHER

NCT02684461 - Phase II Trial of Sequential Consolidation With Pembrolizumab Followed by Nab-paclitaxel | Biotech Hunter | Biotech Hunter